Special Issues in the Management of Depression in Older Patients

Canadian Journal of Psychiatry

Volumn 49, Issue 3 SUPPL. 1, 2004, Pages

  Rabheru, Kiran ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Alzheimer's disease; Antidepressant therapy; Cardiovascular disease; Diabetes; Elderly; Older; Remission; Selective serotonin reuptake inhibitors; Serotonin norepinephrine reuptake inhibitors; Stroke; Vascular dementia

Indexed keywords

AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CATECHOLAMINE; CITALOPRAM; CORTICOTROPIN; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; GLUCOSE; HEMOGLOBIN A1C; IMIPRAMINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ACCOMMODATION PARALYSIS; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ATRIOVENTRICULAR BLOCK; AUTONOMIC DYSFUNCTION; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; FLATULENCE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GERIATRIC CARE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERHIDROSIS; HYPONATREMIA; MAJOR DEPRESSION; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PHARMACODYNAMICS; PHARMACOKINETICS; QT PROLONGATION; QUALITY OF LIFE; RATING SCALE; REMISSION; REVIEW; SIDE EFFECT; STROKE; SUICIDAL BEHAVIOR; TACHYCARDIA; TREMOR; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; GOALS; HUMANS; MIDDLE AGED; PREVALENCE; REMISSION INDUCTION;

EID: 1942505283     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Statistics Canada. CANSIM, Canadian socio-economic database. Table number 052-0001. Ottawa: Statistics Canada; 2003. Available from http://www.statcan.ca/english/Pgdb/demo23a.htm.
2. National, Heart, Lung, and Blood Institute. Morbidity and mortality: 2002. Chartbook on cardiovascular, lung and blood diseases. Bethesda (MD): National Institutes of Health; 2002.
3. Crawford M, Prince M, Menezes P, Mann A. The recognition and treatment of depression in older people in primary care. Int J Geriatr Psychiatry 1998;13:172-6.
4. Teresi J, Abrams R, Holmes D, Ramirez M, Eimicke J. Prevalence of depression and depression recognition in nursing homes. Soc Psychiatry Psychiatr Epidemiol 2001;36:613-20.
5. Steffens D, Skoog I, Norton M, Hart A, Tschanz J, Plassman B, and others. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry 2000;57:601-7.
6. Bland R, Newman S, Orn H. Prevalence of psychiatric disorders in the elderly in Edmonton. Acta Psychiatr Scan Suppl 1988;338:57-63.
7. National Population health survey-public use microdata files-household component. Catalog number 82M0009XCB. Ottawa: Statistics Canada; 1998.
8. McCall N, Parks P, Smith K, Pope G, Griggs M. The prevalence of major depression or dysthymia among aged Medicare Fee-for-Service beneficiaries. Int J Geriatr Psychiatry 2002;17:557-65.
9. Schulman E, Gairola G, Kuder L, McCulloch J. Depression and associated characteristics among community-based elderly people. J Allied Health 2002;31:140-6.
10. Bruce M, McAvay G, Raue P, Brown E, Meyers B, Keohane D, and others. Major depression in elderly home health care patients. Am J Psychiatry 2002;159:1367-74.
11. Schneider G, Kruse A, Nehen H, Senf W, Heuft G. The prevalence and differential diagnosis of subclinical depressive syndromes in inpatients 60 years and older. Psychother Psychosom 2000;69:251-60.
12. Blazer D, Hybels C, Pieper C. The association of depression and mortality in elderly persons: a case for multiple, independent pathways. J Gerontol A Biol Sci Med Sci 2001;56:M505-M509.
13. Schoevers R, Geerlings M, Beekman A, Penninx B, Deeg D, Jonker C, and others. Association of depression and gender with mortality in old age. Results from the Amsterdam Study of the Elderly (AMSTEL). Br J Psychiatry 2000;177:336-42.
14. Schulz R, Beach S, Ives D, Martire L, Ariyo A, Kop W. Association between depression and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2000;160:1761-8.
15. Lavretsky H, Bastani R, Gould R, Huang D, Llorente M, Maxwell A, and others. Predictors of two-year mortality in a prospective "UPBEAT" study of elderly veterans with comorbid medical and psychiatric symptoms. Am J Geriatr Psychiatry 2002;10:458-68.
16. Beckman ATF, Geerlings SW, Deeg DJH, Smit JH, Schoevers RS, de Beurs E, and others. The natural history of late-life depression: a 6-year prospective study in the community. Arch Gen Psychiatry 2002;59:605-11.
17. Newman S, Hassan A. Antidepressant use in the elderly population in Canada: results from a national survey. J Gerontol A Biol Sci Med Sci 1999;54:M527-M30.
18. Riedel-Heller S, Matschinger H, Schork A, Angermeyer M. The utilization of antidepressants in community-dwelling and institutionalized elderly-results from a representative survey in Germany. Pharmacopsychiatry 2001;34:6-12.
19. McDonald W, Salzman C, Schatzberg A. Depression in the elderly. Psychopharmacol Bull 2002;36(Suppl 2):112-22.
20. Lenze E, Mulsant B, Shear M, Schulberg H, Dew M, Begley A, and others. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry 2000;157:722-8.
21. Beckman A, de Beurs E, van Balkom A, Deeg D, van Dyck R, van Tilburg W. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am J Psychiatry 2000;157:89-95.
22. Flint A, Alastair J, Rifat S. Brief reports: recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry 1999;156:943-5.
23. Flint A, Alastair J, Rifat S. Two-year outcome of psychotic depression in late life. Am J Psychiatry 1998;155:178-83.
24. Thorpe L, Whitney D, Kutcher S, Kennedy S. Clinical guidelines for the treatment of depressive disorders. VI. Special populations. Can J Psychiatry 2001;46(Suppl 1):63S-76S.
25. Butters M, Becker J, Nebes R, Zmuda M, Mulsant B, Pollock B, and others. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 2000;157:1949-54.
26. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull 1998;45:210-3.
27. De Vane C, Pollock B. Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry 1999;60(Suppl 20):38-44.
28. Rehman H, Masson E. Neuroendocrinology of ageing. Age Ageing 2001;30:279-87.
29. Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIS. Int Clin Psychopharmacol 1998;13(Suppl 5):S35-S43.
30. Muijsers R, Plosker G, Noble S. Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Drugs Aging 2002;19:377-92.
31. Duckworth G, McBride H. Suicide in old age: a tragedy of neglect. Can J Psychiatry 1996;41:217-22.
32. Skoog I, Aevarsson O, Beskow J, Larsson L, Palsson S, Waern M, and others. Suicidal feelings in a population sample of nondemented 85-year-olds. Am J Psychiatry 1996;153:1015-20.
33. Turvey C, Conwell Y, Jones M, Phillips C, Simonsick E, Pearson J, and others. Risk factors for late-life suicide: a prospective, community-based study. Am J Geriatr Psychiatry 2002;10:398-406.
34. Ticehurst S, Carter G, Clover K, Whyte I, Raymond J, Fryer J. Elderly patients with deliberate self-poisoning treated in an Australian General hospital. Int Psychogeriatr 2002;14:97-105.
35. Doraiswamy P, Khan Z, Donahue R, Richard N. Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. Am J Geriatr Psychiatry 2001;9:423-8.
36. Reynolds C, Frank E, Kupfer D, Thase M, Perel J, Mazumdar S, and others. Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients. Am J Psychiatry 1996;153:1288-92.
37. Katona C, Livingston G. Safety and efficacy of antidepressants in older people. Abstract number S.09.05. J Eur Coll Neuropsychopharmacol 2002;12(Suppl 3):S108.
38. Wilson K, Mottram P, Sivanranthan A, Nightingale A. Antidepressant versus placebo for depressed elderly. Cochrane Database Systematic Review Number 2001:CD000561. Oxford (UK): Cochrane Library; 2001.
39. Bondareff W, Alpert M, Friedhoff A, Richter E, Clary C, Batzar E. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000;157:729-36.
40. Navarro V, Gasto C, Torres X, Marcos T, Pintor L. Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. Acta Psychiatr Scand 2001;103:435-40.
41. Forlenza O, Almeida O, Stoppe A, Hirata E, Ferreira R. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int Psychogeriatr 2001;13:75-84.
42. Newhouse P, Krishnan K, Doraiswamy P, Richter E, Batzar E, Clary C. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000;61:559-68.
43. Cassano G, Puca F, Scapicchio P, Trabucchi M. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002;63:396-402.
44. Schatzberg A, Kremer C, Rodrigues H, Murphy G. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002;10:541-50.
45. Weihs K, Settle E, Batey S, Houser T, Donahue R, Ascher J. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000;61:196-202.
46. Entsuah A, Huang H, Thase M. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869-77.
47. Burrows A, Salzman C, Satlin A, Noble K, Pollock B, Gersh T. A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. Depress Anxiety 2002;15:102-10.
48. Klysner R, Bent-Hansen J, Hansen H, Lunde M, Pleidrup E, Poulsen D, and others. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002;181:29-35.
49. Bump G, Mulsant B, Pollock B, Mazumdar S, Begley A, Dew M, and others. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety 2001;13:38-44.
50. Thase M, Nierenberg A, Keller M, Panagides J. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001;62:782-8.
51. Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002;27:269-80.
52. Weihs K, Houser T, Batey S, Ascher J, Bolden-Watson C, Donahue R, and others. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002;51:753-61.
53. Kunz N, Entsuah R, Lei D, Rudolph R, Hackett D. Venlafaxine extended release [XR] is superior to placebo in relapse prevention for patients with major depressive disorder. Abstract. World Assembly for Mental Health; July 22-27, 2001; Vancouver (BC).
54. Kunz N, Entsuah R, Lei D, Rudolph R, Hackett D. Venlafaxine in the preventive treatment of recurrent major depressive disorder. Abstract. World Assembly for Mental Health; July 22-27, 2001; Vancouver (BC).
55. Thompson L, Coon D, Gallagher-Thompson D, Sommer B, Koin D. Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression. Am J Geriatr Psychiatry 2001;9:225-40.
56. Miller M, Cornes C, Frank E, Ehrenpreis L, Silberman R, Schlemitzauer M, and others. Interpersonal psychotherapy for late-life depression: past, present, and future. J Psychother Pract Res 2001;10:231-8.
57. Lenze E, Dew M, Mazumdar S, Begley A, Cornes C, Miller M, and others. Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: effects on social adjustment. Am J Psychiatry 2002;159:466-8.
58. Reynolds C, Frank E, Perel J, Imber S, Cornes C, Miller M, and others. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999;281:39-45.
59. Wilkinson D, Holmes C, Woolford J, Stammers S, North J. Prophylactic therapy with lithium in elderly patients with unipolar major depression. Int J Geriatr Psychiatry 2002;17:619-22.
60. Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2001;34:119-27.
61. McCall W, Cohen W, Reboussin B, Lawton P. Pretreatment differences in specific symptoms and quality of life among depressed inpatients who do and do not receive electroconvulsive therapy: a hypothesis regarding why the elderly are more likely to receive ECT. J ECT 1999;15:193-201.
62. de Carle A, Kohn R. Electroconvulsive therapy and falls in the elderly. J ECT 2000;16:252-7.
63. Flint A, Rifat S. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry 1998;13:23-8.
64. Kujala, Rosenvinge B, Bekkelund S. Clinical outcome and adverse effects of electroconvulsive therapy in elderly psychiatric patients. J Geriatr Psychiatry Neurol 2002;15:73-6.
65. Rice E, Sombrotto L, Markowitz J, Leon A. Cardiovascular morbidity in high-risk patients during ECT. Am J Psychiatry 1994;151:1637-41.
66. Lockwood K, Alexopoulos G, van Gorp W. Executive dysfunction in geriatric depression. Am J Psychiatry 2002;159:1119-26.
67. Tsolaki M, Fountoulakis K. Effect of antidepressant therapy with venlafaxine in geriatric depression. Int J Geriatr Psychopharmacol 2000;2:83-5.
68. Oxman T. Antidepressants and cognitive impairment in the elderly. J Clin Psychiatry 1996;57(Suppl 5):38-44.
69. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000;403:17-25.
70. Devanand D, Pelton G, Marston K, Camacho Y, Roose S, Stern Y, and others. Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 2003;18:123-30.
71. Lee Y, Choi K, Lee Y. Association of comorbidity with depressive symptoms in community-dwelling older persons. Gerontology 2001;47:254-62.
72. Koenig H. Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry 1998;20:29-43.
73. Gill D, Hatcher S. Antidepressants for depression in medical illness. Cochrane Database Systematic Review number 2000:CD001312. Oxford (UK): Cochrane Library; 2000.
74. Lesperance F, Frasure-Smith N, Talajic M, Bourassa M. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002;105:1049-53.
75. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999-1005.
76. Frasure-Smith N, Lesperance F, Juneau M, Talajic M, Bourassa M. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999;61:26-37.
77. Shiotani I, Sato H, Kinjo K, Nakatani D, Mizuno H, Ohnishi Y, and others. Depressive symptoms predict 12-month prognosis in elderly patients with acute myocardial infarction. J Cardiovasc Risk 2002;9:153-60.
78. Lesperance F, Frasure-Smith N, Juneau M, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000;160:1354-60.
79. Williams S, Kasl S, Heiat A, Abramson J, Krumholz H, Vaccarino V. Depression and risk of heart failure among the elderly: a prospective community-based study. Psychosom Med 2002;64:6-12.
80. Abramson J, Berger A, Krumholz H, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med 2001;161:1725-30.
81. Cohen H, Gibson G, Alderman M. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000;108:2-8.
82. Rodriguez de la Torre B, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H, and others. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001;23:435-40.
83. Shapiro P, Lesperance F, Frasure-Smith N, O'Connor C, Baker B, Jiang J, and others. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. Am Heart J 1999;137:1100-6.
84. Krishnan K, Doraiswamy P, Clary C. Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:347-61.
85. Roose S, Laghrissi-Thode F, Kennedy J, Nelson J, Bigger J, Pollock B, and others. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-91.
86. Nelson J, Kennedy J, Pollock B, Laghrissi-Thode F, Narayan M, Nobler M, and others. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 1999;156:1024-8.
87. Berkman L, Blumenthal J, Burg M, Carney R, Catellier D, Cowan M, and others. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289:3106-16.
88. Larson S, Owens P, Ford D, Eaton W. Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke 2001;32:1979-83.
89. Jonas B, Mussolino M. Symptoms of depression as a prospective risk factor for stroke. Psychosom Med 2000;62:463-71.
90. Pohjasvaara T, Vataja R, Leppavuori A, Kaste M, Erkinjuntti T. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol 2001;8:315-9.
91. Pohjasvaara T, Vataja R, Leppavuori A, Kaste M, Erkinjuntti T. Cognitive functions and depression as predictors of poor outcome 15 months after stroke. Cerebrovasc Dis 2002;14:228-33.
92. Gillen R, Tennen H, McKee T, Gernert-Dott P, Affleck G. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil 2001;82:1645-9.
93. Cole M, Elie L, McCusker J, Bellavance F, Mansour A. Feasibility and effectiveness of treatments for post-stroke depression in elderly inpatients: systematic review. J Geriatr Psychiatry Neurol 2001;14:37-41.
94. Robinson R, Schultz S, Castillo C, Kopel T, Kosier J, Newman R, and others. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;157:351-9.
95. Anderson R, Freedland K, Clouse R, Lustman P. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-78.
96. de Groot M, Anderson R, Freedland K, Clouse R, Lustman P. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63:619-30.
97. Lustman P, Anderson R, Freedland K, de Groot M, Carney R, Clouse R. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934-42.
98. Goodnick P. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001;13:31-41.
99. Stratton I, Adler A, Neil A, UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
100. Ahmad M, Goucke C. Management strategies for the treatment of neuropathic pain in the elderly. Drugs Aging 2002;19:929-45.
101. Jensen P, Larson J. Management of painful diabetic neuropathy. Drugs Aging 2001;18:737-49.
102. Joss J. Tricyclic antidepressant use in diabetic neuropathy. Ann Pharmacother 1999;33:996-1000.
103. Kunz N, Entsuah R, Goli V, Rudolph R, Cantillon M. Effect of venlafaxine extended release on diabetic neuropathic pain. In: New Research Program and Abstracts of Annual Meeting of the American Psychiatric Association (APA). Washington (DC): APA; 2000.
104. Sindrup S, Bach F, Madsen C, Gram L, Jensen T. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003;60:1284-9.
105. Li Y, Meyer J, Thornby J. Depressive symptoms among cognitively normal versus cognitively impaired elderly subjects. Int J Geriatr Psychiatry 2001;16:455-61.
106. Li Y, Meyer J, Thornby J. Longitudinal follow-up of depressive symptoms among normal versus cognitively impaired elderly. Int J Geriatr Psychiatry 2001;16:718-27.
107. Katona C, Hunter B, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998;13:100-8.
108. Magai C, Kennedy G, Cohen C, Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry 2000;8:66-74.
109. Lyketsos C, Sheppard J, Steele C, Kopunek S, Steinberg M, Baker A, and others. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 2000;157:1686-9.
110. Petracca G, Chemerinski E, Starkstein S. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001;13:233-40.
111. Raji M, Brady S. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother 2001;35:1024-7.
112. Gasto C, Navarro V, Marcos T, Portella M, Torra M, Rodamilans M. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 2003;23:21-6.
113. Keller M. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry 2000;61:896-908.
114. Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 2002;17:231-7.
115. Spina E, Scordo M. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002;19:299-320.